Skip to content

Pilot Study to Determine Feasibility of Benign and Malignant Skin Lesion Detection.

Pilot Study to Asses the Identification of Melanoma in Skin Lesions.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02009085
Enrollment
126
Registered
2013-12-11
Start date
2013-06-30
Completion date
2017-06-30
Last updated
2018-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Lesions

Brief summary

In this study a fluorescent contrast dye is applied to a suspicious skin lesion. Images are acquired and processed. The information is used to develop a prediction model for the presence of malignant transformation in the skin.

Detailed description

Images acquired in the study are used for the development of a software analysis program.

Interventions

None listed

Sponsors

Clalit Health Services
CollaboratorOTHER
Orlucent, Inc
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Over the age of 18 * Individual is scheduled for a skin biopsy in toto * The lesion is pigmented or non pigmented * Lesions may be under suspicion for basal cell carcinoma, squamous cell carcinoma, actinic keratosis, nevi, melanoma, seborrheic keratosis. * The lesion is accessible to the imaging device

Exclusion criteria

* The patient has sensitive skin and easily breaks out in rash * The lesion is within 1 cm of the eye * The lesion is on mucosal surfaces (e.g., lips, genitals) * Pregnant females * Taking medications that pigments the skin

Design outcomes

Primary

MeasureTime frameDescription
Correlation between imaging and pathology.No long term follow up is necessary.Patients are imaged and then undergo a biopsy. Images are used to develop a software predicting model based on pathology. Sensitivity and specificity parameters are calculated. No long term follow up is required since the biopsy is performed on the skin imaged. The follow up required is for the pathology for the skin excised.

Secondary

MeasureTime frameDescription
Acute responseup to 1 dayThe acute dermal response to the imaging procedure is evaluated.

Other

MeasureTime frameDescription
None specified.0no other outcome is specified in the .

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026